deCODE genetics (DCGN) Receives Non-Compliance Notification
More News related to DCGN
- deCODE genetics (DCGN) Receives Trading Suspension Letter From Nasdaq
- deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal
- deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
- deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets
- After-Hours Movers 9/17: IHS, GEOY Higher; CLUB, FSP, NMM, SIRI Lower
More News related to Corporate News
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
deCODE genetics (Nasdaq: DCGN) has received a notice from the Nasdaq Stock Market indicating that deCODE is not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for its common stock has been below $1.00 per share for 30 consecutive business days.
In accordance with Nasdaq Listing Rules, deCODE will be provided 180 calendar days, or until March 15, 2010, to regain compliance with the Minimum Bid Price Rule. deCODE can achieve compliance if at any time before March 15, 2010, its common stock closes at $1.00 per share or more for at least 10 consecutive business days. [SM]
Related Categories
Corporate NewsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
